Denali Capital (NASDAQ:DECA) announced in an 8-K that it has added $18 million in equity funding to its combination with biotech firm Longevity through the sale of newly issued series A preferred shares.
FutureTech Capital has agreed to purchase 1,800,000 such shares at $10 per share and Denali plans to issue at least 200,000 more preferred shares to investors not covered in this purchase. When announcing the business combination, Denali noted it aimed to raise a $30 million PIPE and it must provide $30 million in cash in order for the deal to close.
These preferred shares will be convertible into ordinary shares at the lower of $8 or the 20-day VWAP of the company stock multiplied by 80%. The parties have set a floor price for such conversion at $5 and all prices may be further adjusted for dividends, stock splits or other corporate actions. Otherwise, these preferred shares will have the same voting power and dividend rights as ordinary shares.
Denali Capital initially announced its $236.2 million combination with Longevity in January. Bothell, Washington-based Longevity is building a platform to consolidate a number of clinical-stage therapies, beginning with treatment candidates aiming to improve outcomes of certain vascular conditions as well as replace lost tissue.
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...
M3-Brigade V (NASDAQ:MBAV) has entered into a definitive agreement to combine with crypto treasury firm ReserveOne, assembling about $1 billion in equity funding. ReserveOne is setting up a diversified Bitcoin and digital asset treasury with a portion of its investments going towards blockchain infrastructure and venture raises. The combined company is expected to trade on...
At the SPAC of Dawn As the SPAC market has warmed in 2025, only 21 of the 70 SPACs (30%) that have IPO’d thus far have overfunded their trusts to draw in investors and none of these funded to more than 101%. By contrast, 87% of 2023 SPACs were overfunded – some to as high...
Emmis Acquisition Corporation (NASDAQ:EMISU) has filed for a $100 million SPAC to take a look at the manufacturing sector after a few unique wrinkles in their IPO process. Initial investors are set to receive one right to a 1/10 share in each unit purchased and the SPAC will have 18 months to complete a business...
Chenghe III (NASDAQ:CHEC.U) has filed for a $110 million SPAC to continue the team’s growing series while turning to a new underwriter. The new SPAC is offering investors a 1/2 warrant in each unit and no overfunding of the trust, but it will need to complete a business combination within 18 months of its IPO...